Calvin Blissett on X
$IRWD: Citizens raised from 8 to 10, profitable FDA approved biotech, raised guidance (second time in a year) to 450m-475m revenue vs 320m est. Bought VectivBio for 1b. Market cap 682m Q2 2026 earnings: LINZESS Pricing Power Powers a Guidance Raise Ironwood Pharmaceuticals delivered a robust Q2 2026, breaking past conservative Q1 expectations by posting $113M in total revenue (+33% YoY) and raising its full-year guidance across the board. The story here is a massive rebound in LINZESS net pricing. The elimination of inflationary rebates drove commercial margins to 78% (up from 69% a year ago). The company capitalized on this cash flow by paying off $200M in convertible notes with cash on hand, effectively de-risking the balance sheet ahead of heavy R&D investments for the apraglutide STARS-2 trial. Full article with charts - link in bio ๐ ๐๐ฎ๐ฅ๐ฅ ๐๐๐ฌ๐ โข ๐๐ซ๐ข๐๐ข๐ง๐ ๐๐จ๐ฐ๐๐ซ ๐๐๐ฌ๐ญ๐จ๐ซ๐๐ โ The strategic reset of the LINZESS list price at the start of 2026 is paying massive dividends. Favorable gross-to-net rebate timing and eliminated inflationary rebates are driving net sales and commercial margins higher, resulting in a full-year guidance raise. โข ๐๐๐ฅ๐๐ง๐๐ ๐๐ก๐๐๐ญ ๐๐-๐ซ๐ข๐ฌ๐ค๐๐ โ The $200M cash repayment of 2026 convertible notes removes a major maturity overhang, leaving the company well-positioned to self-fund the critical Phase 3 apraglutide trial while generating strong free cash flow. ๐ท ๐๐๐๐ซ ๐๐๐ฌ๐ โข ๐๐จ๐ฅ๐ฎ๐ฆ๐ ๐๐ซ๐จ๐ฐ๐ญ๐ก ๐๐จ๐ซ๐ฆ๐๐ฅ๐ข๐ณ๐ข๐ง๐ โ Despite the net pricing win, LINZESS prescription demand growth decelerated to 4% YoY in Q2, down from 5% in Q1 and the 11-13% growth rates seen in late 2025. The brand is reaching maturity. โข ๐๐๐๐ฏ๐ฒ ๐๐๐ฅ๐ข๐๐ง๐๐ ๐จ๐ง ๐๐ง๐ ๐๐ฌ๐ฌ๐๐ญ โ Almost 100% of Ironwood's revenue comes from its share of LINZESS profits. With no clear post-LOE strategy communicated, long-term terminal value remains a risk while the pipeline remains highly concentrated on apraglutide. ๐ทBullish. Management is executing flawlessly on their stated goals: maximizing LINZESS cash flow, strengthening the balance sheet, and advancing apraglutide. The guidance raise confirms Q1's strength was not a fluke. ๐๐๐ฒ ๐๐ก๐๐ฆ๐๐ฌ ๐ท ๐๐๐๐๐๐๐ ๐๐จ๐ฆ๐ฆ๐๐ซ๐๐ข๐๐ฅ ๐๐๐ซ๐ ๐ข๐ง๐ฌ ๐๐ฑ๐ฉ๐๐ง๐๐ข๐ง๐ [NEW] Accelerating. LINZESS commercial margin jumped to 78% in Q2 2026 from 69% in Q2 2025. This was driven by a combination of a 14% increase in U. S. net sales (to $282.3M) and a YoY decrease in AbbVie/Ironwood commercial costs and discounts (from $76.9M to $63.0M). The January 2026 list price reduction successfully eliminated significant inflationary rebates, directly benefiting the bottom line. ๐ท ๐๐๐ฅ๐๐ง๐๐ ๐๐ก๐๐๐ญ ๐๐๐ฅ๐๐ฏ๐๐ซ๐๐ ๐ข๐ง๐ ๐๐ฑ๐๐๐ฎ๐ญ๐๐ [NEW] Stable. The company successfully executed its plan to repay the $200M aggregate principal amount of its 1.50% convertible senior notes at maturity in June using cash on hand. While cash balances dropped from $220.5M in Q1 to $79.1M, eliminating this near-term maturity removes a significant financial overhang. The remaining $385M on the revolving credit facility represents manageable leverage against >$310M in projected FY26 Adjusted EBITDA. ๐ท ๐๐๐๐๐๐๐ ๐๐ซ๐๐ฌ๐๐ซ๐ข๐ฉ๐ญ๐ข๐จ๐ง ๐๐๐ฆ๐๐ง๐ ๐๐๐๐๐ฅ๐๐ซ๐๐ญ๐ข๐ง๐ [NEW] Decelerating. A specific data point contradicts the purely positive narrative: while revenue and profits are surging due to pricing, the underlying prescription volume growth is slowing. Q2 Rx demand grew 4% YoY (59.8M capsules). This marks a sequential deceleration from 5% in Q1 2026, and is down significantly from the 12-13% growth rates experienced in the second half of 2025. Management raised demand guidance to 'mid-single digits,' but the multi-year volume trend is clearly cooling. ๐ท ๐๐ข๐ ๐ง๐ข๐๐ข๐๐๐ง๐ญ ๐๐ง๐๐จ๐ฆ๐ ๐๐๐ฑ ๐๐จ๐ง-๐๐๐ฌ๐ก ๐๐ซ๐๐ Stable. Ironwood recorded $22.4M in income tax expense in Q2 (vs $14.2M in Q2 25). The majority of this is non-cash as the company utilizes net operating losses (NOLs). While it doesn't impact immediate cash flow, it continually depresses GAAP EPS and highlights the complex tax situation of historical R&D-heavy biotech models. ๐๐ญ๐ก๐๐ซ ๐๐๐๐ฌ ๐๐๐ฃ๐ฎ๐ฌ๐ญ๐๐ ๐๐๐๐๐๐: $83.0 million Accelerating. Up 66% YoY from $50.1M in Q2 2025. The companyโs focus on expense discipline combined with the rebound in LINZESS net pricing continues to generate massive operating leverage. ๐๐ฉ๐๐ซ๐๐ญ๐ข๐ง๐ ๐๐๐ฌ๐ก ๐ ๐ฅ๐จ๐ฐ: $58.3 million Reversing positively. A massive swing from Q2 2025, which saw cash from operations at a negative $15.1 million. This robust cash generation enabled the $200M debt repayment without tapping into further credit facilities. ๐๐ฎ๐ข๐๐๐ง๐๐ ๐ ๐๐๐ ๐๐จ๐ญ๐๐ฅ ๐๐๐ฏ๐๐ง๐ฎ๐: $460 - $485 million Accelerating. Raised from the prior estimate of $450 - $475M. At the midpoint ($472.5M), this represents an acceleration over the $290 - $310M baseline seen in 2025, heavily driven by the LINZESS pricing structure changes. ๐ ๐๐๐ ๐๐๐ฃ๐ฎ๐ฌ๐ญ๐๐ ๐๐๐๐๐๐: >$310 million Accelerating. Raised from the prior floor of >$300 million. Proves that the incremental revenue gains from LINZESS are dropping almost entirely to the bottom line. ๐ ๐๐๐ ๐ดle-rate debt versus building cash for business development? ๐๐๐๐๐-๐ ๐๐ง๐ซ๐จ๐ฅ๐ฅ๐ฆ๐๐ง๐ญ ๐๐ฉ๐๐๐ With STARS-2 actively recruiting, are you seeing any enrollment headwinds due to competing GLP-2 trials in the SBS-IF space, and when should investors expect completion of enrollment? ๐ด
